Literature DB >> 12377805

Observer variation in the diagnosis of superficial oesophageal adenocarcinoma.

A H Ormsby1, R E Petras, W H Henricks, T W Rice, L A Rybicki, J E Richter, J R Goldblum.   

Abstract

BACKGROUND AND AIMS: When to perform oesophagectomy for neoplastic progression in Barrett's oesophagus is controversial. Some resect for high grade dysplasia whereas others defer treatment until intramucosal adenocarcinoma is diagnosed. Interobserver agreement for a diagnosis of high grade dysplasia or intramucosal adenocarcinoma remains unknown and may have therapeutic implications.
METHODS: Histological slides from 75 oesophagectomy specimens with high grade dysplasia or T(1) adenocarcinoma were blindly reviewed by two gastrointestinal pathologists and one general surgical pathologist, and classified as high grade dysplasia, intramucosal adenocarcinoma, or submucosal adenocarcinoma. A subsequent re-review of all 75 cases by the same observers following establishment of uniform histological criteria was undertaken. Interobserver agreement was determined by kappa statistics. Coefficients <0.21, 0.21-0.40, 0.41-0.60, 0.61-0.80, and >0.80 were considered poor, fair, moderate, good, and very good agreement, respectively.
RESULTS: Interobserver agreement among all pathologists and between gastrointestinal pathologists when comparing high grade dysplasia with intramucosal adenocarcinoma was only fair (k=0.42; 0.56, respectively) and did not substantially improve on subsequent re-evaluation following establishment of uniform histological criteria (K=0.50; 0.61, respectively).
CONCLUSIONS: When evaluating resection specimens and after implementation of uniform histological criteria, even experienced gastrointestinal pathologists frequently disagree on a diagnosis of high grade dysplasia versus intramucosal adenocarcinoma. Treatment strategies based on the histological distinction of high grade dysplasia from intramucosal adenocarcinoma using limited biopsy specimens should be re-evaluated.

Entities:  

Mesh:

Year:  2002        PMID: 12377805      PMCID: PMC1773435          DOI: 10.1136/gut.51.5.671

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

1.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

2.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Increased expression of the cyclin D1 gene in Barrett's esophagus.

Authors:  N Arber; C Lightdale; H Rotterdam; K H Han; A Sgambato; E Yap; H Ahsan; J Finegold; P D Stevens; P H Green; H Hibshoosh; A I Neugut; P R Holt; I B Weinstein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-06       Impact factor: 4.254

4.  Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy.

Authors:  R F Heitmiller; M Redmond; S R Hamilton
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

5.  p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  C A Moskaluk; R Heitmiller; M Zahurak; D Schwab; D Sidransky; S R Hamilton
Journal:  Hum Pathol       Date:  1996-11       Impact factor: 3.466

6.  p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia.

Authors:  M Younes; A Ertan; L V Lechago; J R Somoano; J Lechago
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

7.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

8.  Surgical management of high-grade dysplasia in Barrett's esophagus.

Authors:  T W Rice; G W Falk; E Achkar; R E Petras
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

9.  The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.

Authors:  W Polkowski; J J van Lanschot; F J Ten Kate; J P Baak; G N Tytgat; H Obertop; W J Voorn; G J Offerhaus
Journal:  Surg Oncol       Date:  1995-06       Impact factor: 3.279

10.  Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.

Authors:  K K Krishnadath; H W Tilanus; M van Blankenstein; F T Bosman; A H Mulder
Journal:  J Pathol       Date:  1995-02       Impact factor: 7.996

View more
  47 in total

1.  Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works?

Authors:  D Alderson
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 2.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

3.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 4.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 5.  Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?

Authors:  Vani J A Konda; Mark K Ferguson
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

Review 6.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

7.  Diagnosis and management of Barrett's esophagus for the endoscopist.

Authors:  Sagar S Garud; Steven Keilin; Qiang Cai; Field F Willingham
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 8.  Endoscopic therapy for Barrett's oesophagus.

Authors:  H Barr; N Stone; B Rembacken
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

9.  Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus.

Authors:  John A Evans; John M Poneros; Brett E Bouma; Jason Bressner; Elkan F Halpern; Milen Shishkov; Gregory Y Lauwers; Mari Mino-Kenudson; Norman S Nishioka; Guillermo J Tearney
Journal:  Clin Gastroenterol Hepatol       Date:  2006-01       Impact factor: 11.382

10.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.